West Pharmaceutical
WST
#879
Rank
$22.57 B
Marketcap
$311.66
Share price
2.49%
Change (1 day)
-10.71%
Change (1 year)
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company produces rubber components for packaging injectable drugs and for providing a sterile environment.

P/E ratio for West Pharmaceutical (WST)

P/E ratio as of November 2024 (TTM): 41.5

According to West Pharmaceutical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 41.4993. At the end of 2022 the company had a P/E ratio of 29.9.

P/E ratio history for West Pharmaceutical from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202229.9-43.12%
202152.6-12.96%
202060.431.4%
201946.031.31%
201835.0-27.26%
201748.111.21%
201643.3-4.41%
201545.352.23%
201429.7-2.09%
201330.431.5%
201223.136.36%
201116.9-19.4%
201021.017.97%
200917.825.02%
200814.3-24.15%
200718.8-23.7%
200624.645.63%
200516.9-22.97%
200422.093.01%
200311.4-39.39%
200218.8-126.11%
2001-71.9

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
40.1-3.44%๐Ÿ‡บ๐Ÿ‡ธ USA
16.4-60.38%๐Ÿ‡บ๐Ÿ‡ธ USA
-83.0-299.92%๐Ÿ‡บ๐Ÿ‡ธ USA
56.6 36.47%๐Ÿ‡บ๐Ÿ‡ธ USA
6.37-84.64%๐Ÿ‡บ๐Ÿ‡ธ USA
21.8-47.48%๐Ÿ‡บ๐Ÿ‡ธ USA
30.9-25.49%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
10.9-73.81%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.